Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia hello@breathelifesciences.com +61 2 9078 8180BLS Pharmaceuticals Ltd | ASX:BLS | www.blspharma.com 1 15 October 2026 Quarterly Activities Report Period Ending 30 September 2026 Record $26.7 million Q1 revenue provides strong start to...
BLS Quarterly Activities Report September 2026 Revised
Filed with ASX · · 11 pages · English
Summary by 6ix AI
The report indicates a significant increase in revenue driven by higher manufacturing volumes and ongoing international supply agreements, particularly in Germany. The company also reaffirmed its guidance for the financial year, expecting substantial revenue growth supported by increased manufacturing capacity and new customer onboarding. Additionally, BLS is expanding its international operations, including the development of a GMP facility in Scotland to enhance its manufacturing capabilities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
BLS Pharmaceuticals Limited on 6ix
Story so far
Earlier from BLS Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Ceasing to be a substantial holder
- Becoming a substantial holder
- AGM Date and Director Nominations
- Application for quotation of securities - BLS
Later from BLS Pharmaceuticals
- Q1 FY2027 Quarterly Activities Update
- Notice of Annual General Meeting/Proxy Form
- Letter to Shareholders re Annual General Meeting
- Directors Change of Interest Notice X 2
Follow BLS Pharmaceuticals into a list and get an email when it puts out news.
Follow BLS Pharmaceuticals